|
Years of exposure to disease-modifying antirheumatic drugs and cardiovascular morbidity in patients with rheumatoid arthritis in the QUEST-RA study |
|||||
| HRa (95% CI) CV all types |
HRb (95% CI) CV all types |
HRc (95% CI) |
|||
|
|
|
||||
| CV all types |
Myocardial infarction |
Stroke |
|||
|
|
|||||
| Methotrexate |
0.82 (0.79–0.86)d |
0.84 (0.80–0.87)d |
0.85 (0.81–0.89)d |
0.82 (0.74–0.91)d |
0.89 (0.82–0.98)e |
| Glucocorticoids |
0.94 (0.92–0.97)d |
0.95 (0.93–0.97)d |
0.95 (0.92–0.98)d |
0.96 (0.91–1.00) |
0.98 (0.93–1.03) |
| Antimalarials |
0.94 (0.91–0.98)f |
0.95 (0.91–0.99)f |
0.98 (0.94–1.02) |
0.94 (0.85–1.03) |
0.87 (0.76–1.01) |
| Sulfasalazine |
0.91 (0.87–0.96)d |
0.92 (0.88–0.97)f |
0.92 (0.87–0.98)f |
0.82 (0.69–0.98)e |
0.90 (0.79–1.03) |
| Gold |
0.96 (0.92–1.00)e |
0.96 (0.92–1.00)e |
0.99 (0.95–1.03) |
1.04 (0.98–1.10) |
0.98 (0.89–1.07) |
| Leflunomide |
0.52 (0.38–0.72)d |
0.55 (0.41–0.75)d |
0.59 (0.43–0.79)f |
0.52 (0.26–1.06) |
0.91 (0.65–1.28) |
| TNF-α blockers |
0.67 (0.53–0.85)f |
0.71 (0.56–0.89)f |
0.64 (0.49–0.83)f |
0.42 (0.21–0.81)e |
0.64 (0.39–1.05) |
|
aCrude hazard ratio. bAdjusted hazard ratio by age and gender. cAdjusted hazard ratio by age, gender, disease activity/severity (DAS 28 [disease activity score using 28 joint counts] and Health Assessment Questionnaire), rheumatoid arthritis characteristics (rheumatoid factor-positive and extra-articular manifestations), and traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking ever, and obesity). dP < 0.001. eP < 0.05. fP < 0.01. CI, confidence interval; CV, cardiovascular; QUEST-RA, Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis; TNF-α, tumor necrosis factor-alpha. | |||||
Naranjo et al. Arthritis Research & Therapy 2008 10:R30 doi:10.1186/ar2383 |
|||||